nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—VDAC2—blood plasma—acquired immunodeficiency syndrome	0.038	0.0837	CbGeAlD
Dihydroxyaluminium—VDAC1—blood plasma—acquired immunodeficiency syndrome	0.0301	0.0663	CbGeAlD
Dihydroxyaluminium—VDAC2—skin of body—acquired immunodeficiency syndrome	0.0183	0.0403	CbGeAlD
Dihydroxyaluminium—Pulmonary congestion—Delavirdine—acquired immunodeficiency syndrome	0.0171	0.0322	CcSEcCtD
Dihydroxyaluminium—Toxicity to various agents—Saquinavir—acquired immunodeficiency syndrome	0.0161	0.0303	CcSEcCtD
Dihydroxyaluminium—VDAC3—skin of body—acquired immunodeficiency syndrome	0.0152	0.0335	CbGeAlD
Dihydroxyaluminium—VDAC1—Gemcitabine—Lamivudine—acquired immunodeficiency syndrome	0.015	1	CbGdCrCtD
Dihydroxyaluminium—VDAC2—lymphoid tissue—acquired immunodeficiency syndrome	0.0148	0.0326	CbGeAlD
Dihydroxyaluminium—VDAC2—digestive system—acquired immunodeficiency syndrome	0.0146	0.0322	CbGeAlD
Dihydroxyaluminium—VDAC1—skin of body—acquired immunodeficiency syndrome	0.0145	0.0319	CbGeAlD
Dihydroxyaluminium—Respiratory tract congestion—Delavirdine—acquired immunodeficiency syndrome	0.0141	0.0266	CcSEcCtD
Dihydroxyaluminium—VDAC2—blood—acquired immunodeficiency syndrome	0.0139	0.0307	CbGeAlD
Dihydroxyaluminium—VDAC2—spinal cord—acquired immunodeficiency syndrome	0.0134	0.0296	CbGeAlD
Dihydroxyaluminium—VDAC2—lung—acquired immunodeficiency syndrome	0.0122	0.0269	CbGeAlD
Dihydroxyaluminium—VDAC3—digestive system—acquired immunodeficiency syndrome	0.0122	0.0268	CbGeAlD
Dihydroxyaluminium—VDAC1—lymphoid tissue—acquired immunodeficiency syndrome	0.0117	0.0258	CbGeAlD
Dihydroxyaluminium—VDAC3—blood—acquired immunodeficiency syndrome	0.0116	0.0256	CbGeAlD
Dihydroxyaluminium—VDAC1—digestive system—acquired immunodeficiency syndrome	0.0116	0.0255	CbGeAlD
Dihydroxyaluminium—Electrolyte imbalance—Ritonavir—acquired immunodeficiency syndrome	0.0114	0.0215	CcSEcCtD
Dihydroxyaluminium—VDAC2—nervous system—acquired immunodeficiency syndrome	0.0113	0.0249	CbGeAlD
Dihydroxyaluminium—VDAC3—bone marrow—acquired immunodeficiency syndrome	0.0112	0.0247	CbGeAlD
Dihydroxyaluminium—VDAC3—spinal cord—acquired immunodeficiency syndrome	0.0112	0.0246	CbGeAlD
Dihydroxyaluminium—Acidosis—Zidovudine—acquired immunodeficiency syndrome	0.0111	0.0209	CcSEcCtD
Dihydroxyaluminium—VDAC1—blood—acquired immunodeficiency syndrome	0.011	0.0243	CbGeAlD
Dihydroxyaluminium—VDAC2—central nervous system—acquired immunodeficiency syndrome	0.0109	0.024	CbGeAlD
Dihydroxyaluminium—VDAC3—vagina—acquired immunodeficiency syndrome	0.0108	0.0237	CbGeAlD
Dihydroxyaluminium—VDAC1—bone marrow—acquired immunodeficiency syndrome	0.0107	0.0235	CbGeAlD
Dihydroxyaluminium—VDAC1—spinal cord—acquired immunodeficiency syndrome	0.0106	0.0234	CbGeAlD
Dihydroxyaluminium—VDAC1—vagina—acquired immunodeficiency syndrome	0.0102	0.0225	CbGeAlD
Dihydroxyaluminium—VDAC3—lung—acquired immunodeficiency syndrome	0.0102	0.0224	CbGeAlD
Dihydroxyaluminium—Lung disorder—Stavudine—acquired immunodeficiency syndrome	0.00998	0.0188	CcSEcCtD
Dihydroxyaluminium—VDAC1—lung—acquired immunodeficiency syndrome	0.00968	0.0213	CbGeAlD
Dihydroxyaluminium—TNNC1—blood—acquired immunodeficiency syndrome	0.00947	0.0208	CbGeAlD
Dihydroxyaluminium—VDAC3—nervous system—acquired immunodeficiency syndrome	0.00943	0.0207	CbGeAlD
Dihydroxyaluminium—VDAC3—central nervous system—acquired immunodeficiency syndrome	0.00907	0.02	CbGeAlD
Dihydroxyaluminium—VDAC1—nervous system—acquired immunodeficiency syndrome	0.00897	0.0197	CbGeAlD
Dihydroxyaluminium—VDAC2—brain—acquired immunodeficiency syndrome	0.00865	0.019	CbGeAlD
Dihydroxyaluminium—VDAC1—central nervous system—acquired immunodeficiency syndrome	0.00863	0.019	CbGeAlD
Dihydroxyaluminium—VDAC2—lymph node—acquired immunodeficiency syndrome	0.00836	0.0184	CbGeAlD
Dihydroxyaluminium—TNNC1—lung—acquired immunodeficiency syndrome	0.0083	0.0183	CbGeAlD
Dihydroxyaluminium—Acidosis—Lamivudine—acquired immunodeficiency syndrome	0.00791	0.0149	CcSEcCtD
Dihydroxyaluminium—VDAC3—brain—acquired immunodeficiency syndrome	0.0072	0.0159	CbGeAlD
Dihydroxyaluminium—VDAC3—lymph node—acquired immunodeficiency syndrome	0.00696	0.0153	CbGeAlD
Dihydroxyaluminium—VDAC1—brain—acquired immunodeficiency syndrome	0.00685	0.0151	CbGeAlD
Dihydroxyaluminium—Lung disorder—Ritonavir—acquired immunodeficiency syndrome	0.00674	0.0127	CcSEcCtD
Dihydroxyaluminium—VDAC1—lymph node—acquired immunodeficiency syndrome	0.00662	0.0146	CbGeAlD
Dihydroxyaluminium—Cardiovascular disorder—Indinavir—acquired immunodeficiency syndrome	0.0065	0.0122	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Saquinavir—acquired immunodeficiency syndrome	0.00649	0.0122	CcSEcCtD
Dihydroxyaluminium—TNNC1—lymph node—acquired immunodeficiency syndrome	0.00568	0.0125	CbGeAlD
Dihydroxyaluminium—Cardiovascular disorder—Ritonavir—acquired immunodeficiency syndrome	0.00543	0.0102	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Saquinavir—acquired immunodeficiency syndrome	0.00523	0.00985	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Zidovudine—acquired immunodeficiency syndrome	0.00517	0.00974	CcSEcCtD
Dihydroxyaluminium—Polyuria—Zidovudine—acquired immunodeficiency syndrome	0.00507	0.00956	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Delavirdine—acquired immunodeficiency syndrome	0.00501	0.00944	CcSEcCtD
Dihydroxyaluminium—Lightheadedness—Efavirenz—acquired immunodeficiency syndrome	0.00482	0.00909	CcSEcCtD
Dihydroxyaluminium—Dehydration—Nelfinavir—acquired immunodeficiency syndrome	0.00478	0.00901	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Efavirenz—acquired immunodeficiency syndrome	0.00452	0.00852	CcSEcCtD
Dihydroxyaluminium—Polyuria—Efavirenz—acquired immunodeficiency syndrome	0.00446	0.0084	CcSEcCtD
Dihydroxyaluminium—Coma—Ritonavir—acquired immunodeficiency syndrome	0.00436	0.00822	CcSEcCtD
Dihydroxyaluminium—Polyuria—Delavirdine—acquired immunodeficiency syndrome	0.00427	0.00804	CcSEcCtD
Dihydroxyaluminium—Lightheadedness—Saquinavir—acquired immunodeficiency syndrome	0.00411	0.00774	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Ritonavir—acquired immunodeficiency syndrome	0.00402	0.00758	CcSEcCtD
Dihydroxyaluminium—Polyuria—Ritonavir—acquired immunodeficiency syndrome	0.00394	0.00743	CcSEcCtD
Dihydroxyaluminium—Thirst—Delavirdine—acquired immunodeficiency syndrome	0.00394	0.00742	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Saquinavir—acquired immunodeficiency syndrome	0.00385	0.00726	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Delavirdine—acquired immunodeficiency syndrome	0.00376	0.00709	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Lamivudine—acquired immunodeficiency syndrome	0.00369	0.00696	CcSEcCtD
Dihydroxyaluminium—Chills—Didanosine—acquired immunodeficiency syndrome	0.00366	0.00691	CcSEcCtD
Dihydroxyaluminium—Thirst—Ritonavir—acquired immunodeficiency syndrome	0.00364	0.00686	CcSEcCtD
Dihydroxyaluminium—Polyuria—Lamivudine—acquired immunodeficiency syndrome	0.00362	0.00682	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Nelfinavir—acquired immunodeficiency syndrome	0.00357	0.00672	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Stavudine—acquired immunodeficiency syndrome	0.00355	0.0067	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Saquinavir—acquired immunodeficiency syndrome	0.00352	0.00663	CcSEcCtD
Dihydroxyaluminium—Thirst—Saquinavir—acquired immunodeficiency syndrome	0.0035	0.0066	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Indinavir—acquired immunodeficiency syndrome	0.00349	0.00657	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Saquinavir—acquired immunodeficiency syndrome	0.00335	0.00631	CcSEcCtD
Dihydroxyaluminium—Thirst—Lamivudine—acquired immunodeficiency syndrome	0.00334	0.0063	CcSEcCtD
Dihydroxyaluminium—Urinary retention—Ritonavir—acquired immunodeficiency syndrome	0.00329	0.00621	CcSEcCtD
Dihydroxyaluminium—Dehydration—Ritonavir—acquired immunodeficiency syndrome	0.00322	0.00607	CcSEcCtD
Dihydroxyaluminium—Chills—Stavudine—acquired immunodeficiency syndrome	0.00318	0.006	CcSEcCtD
Dihydroxyaluminium—Chills—Abacavir—acquired immunodeficiency syndrome	0.00313	0.00591	CcSEcCtD
Dihydroxyaluminium—Dehydration—Saquinavir—acquired immunodeficiency syndrome	0.0031	0.00584	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Zidovudine—acquired immunodeficiency syndrome	0.00309	0.00582	CcSEcCtD
Dihydroxyaluminium—Back pain—Nelfinavir—acquired immunodeficiency syndrome	0.00299	0.00564	CcSEcCtD
Dihydroxyaluminium—Back pain—Stavudine—acquired immunodeficiency syndrome	0.00299	0.00563	CcSEcCtD
Dihydroxyaluminium—Dehydration—Lamivudine—acquired immunodeficiency syndrome	0.00296	0.00557	CcSEcCtD
Dihydroxyaluminium—Infection—Didanosine—acquired immunodeficiency syndrome	0.00288	0.00543	CcSEcCtD
Dihydroxyaluminium—Chills—Zidovudine—acquired immunodeficiency syndrome	0.00277	0.00521	CcSEcCtD
Dihydroxyaluminium—Vertigo—Abacavir—acquired immunodeficiency syndrome	0.00273	0.00515	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Efavirenz—acquired immunodeficiency syndrome	0.00271	0.00512	CcSEcCtD
Dihydroxyaluminium—Convulsion—Nelfinavir—acquired immunodeficiency syndrome	0.00268	0.00505	CcSEcCtD
Dihydroxyaluminium—Convulsion—Abacavir—acquired immunodeficiency syndrome	0.00263	0.00496	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Efavirenz—acquired immunodeficiency syndrome	0.00261	0.00492	CcSEcCtD
Dihydroxyaluminium—Oedema—Nevirapine—acquired immunodeficiency syndrome	0.00261	0.00492	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Delavirdine—acquired immunodeficiency syndrome	0.0026	0.00489	CcSEcCtD
Dihydroxyaluminium—Back pain—Zidovudine—acquired immunodeficiency syndrome	0.00259	0.00489	CcSEcCtD
Dihydroxyaluminium—Chills—Indinavir—acquired immunodeficiency syndrome	0.00257	0.00485	CcSEcCtD
Dihydroxyaluminium—Oedema—Nelfinavir—acquired immunodeficiency syndrome	0.00253	0.00476	CcSEcCtD
Dihydroxyaluminium—Oedema—Abacavir—acquired immunodeficiency syndrome	0.00248	0.00468	CcSEcCtD
Dihydroxyaluminium—Pain—Didanosine—acquired immunodeficiency syndrome	0.00248	0.00468	CcSEcCtD
Dihydroxyaluminium—Infection—Abacavir—acquired immunodeficiency syndrome	0.00247	0.00465	CcSEcCtD
Dihydroxyaluminium—Back pain—Indinavir—acquired immunodeficiency syndrome	0.00241	0.00455	CcSEcCtD
Dihydroxyaluminium—Vertigo—Zidovudine—acquired immunodeficiency syndrome	0.00241	0.00454	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Ritonavir—acquired immunodeficiency syndrome	0.0024	0.00453	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Indinavir—acquired immunodeficiency syndrome	0.00235	0.00443	CcSEcCtD
Dihydroxyaluminium—Chills—Delavirdine—acquired immunodeficiency syndrome	0.00232	0.00438	CcSEcCtD
Dihydroxyaluminium—Convulsion—Zidovudine—acquired immunodeficiency syndrome	0.00232	0.00438	CcSEcCtD
Dihydroxyaluminium—Hypotension—Abacavir—acquired immunodeficiency syndrome	0.00232	0.00437	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Saquinavir—acquired immunodeficiency syndrome	0.00231	0.00436	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Ritonavir—acquired immunodeficiency syndrome	0.00231	0.00435	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.00229	0.00432	CcSEcCtD
Dihydroxyaluminium—Back pain—Efavirenz—acquired immunodeficiency syndrome	0.00228	0.0043	CcSEcCtD
Dihydroxyaluminium—Vertigo—Indinavir—acquired immunodeficiency syndrome	0.00224	0.00422	CcSEcCtD
Dihydroxyaluminium—Pain—Nevirapine—acquired immunodeficiency syndrome	0.00223	0.0042	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Saquinavir—acquired immunodeficiency syndrome	0.00222	0.00419	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Efavirenz—acquired immunodeficiency syndrome	0.00222	0.00419	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Lamivudine—acquired immunodeficiency syndrome	0.00221	0.00416	CcSEcCtD
Dihydroxyaluminium—Oedema—Zidovudine—acquired immunodeficiency syndrome	0.00219	0.00413	CcSEcCtD
Dihydroxyaluminium—Back pain—Delavirdine—acquired immunodeficiency syndrome	0.00218	0.00411	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.00218	0.0041	CcSEcCtD
Dihydroxyaluminium—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.00216	0.00407	CcSEcCtD
Dihydroxyaluminium—Pain—Stavudine—acquired immunodeficiency syndrome	0.00215	0.00406	CcSEcCtD
Dihydroxyaluminium—Chills—Ritonavir—acquired immunodeficiency syndrome	0.00215	0.00405	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.00214	0.00403	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.00213	0.00401	CcSEcCtD
Dihydroxyaluminium—Pain—Abacavir—acquired immunodeficiency syndrome	0.00212	0.004	CcSEcCtD
Dihydroxyaluminium—Vertigo—Efavirenz—acquired immunodeficiency syndrome	0.00212	0.00399	CcSEcCtD
Dihydroxyaluminium—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.00207	0.00391	CcSEcCtD
Dihydroxyaluminium—Chills—Saquinavir—acquired immunodeficiency syndrome	0.00207	0.0039	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.00206	0.00389	CcSEcCtD
Dihydroxyaluminium—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.00204	0.00385	CcSEcCtD
Dihydroxyaluminium—Oedema—Indinavir—acquired immunodeficiency syndrome	0.00204	0.00384	CcSEcCtD
Dihydroxyaluminium—Vertigo—Delavirdine—acquired immunodeficiency syndrome	0.00203	0.00382	CcSEcCtD
Dihydroxyaluminium—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.00202	0.00381	CcSEcCtD
Dihydroxyaluminium—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.00202	0.0038	CcSEcCtD
Dihydroxyaluminium—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.00201	0.00378	CcSEcCtD
Dihydroxyaluminium—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.002	0.00377	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.002	0.00376	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.00199	0.00375	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00199	0.00374	CcSEcCtD
Dihydroxyaluminium—Chills—Lamivudine—acquired immunodeficiency syndrome	0.00197	0.00372	CcSEcCtD
Dihydroxyaluminium—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.00197	0.00371	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.00197	0.0037	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.00196	0.0037	CcSEcCtD
Dihydroxyaluminium—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.00194	0.00366	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00192	0.00362	CcSEcCtD
Dihydroxyaluminium—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00189	0.00356	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.00188	0.00354	CcSEcCtD
Dihydroxyaluminium—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.00187	0.00353	CcSEcCtD
Dihydroxyaluminium—Pain—Zidovudine—acquired immunodeficiency syndrome	0.00187	0.00353	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00186	0.00351	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.00186	0.0035	CcSEcCtD
Dihydroxyaluminium—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.00185	0.00349	CcSEcCtD
Dihydroxyaluminium—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.00184	0.00348	CcSEcCtD
Dihydroxyaluminium—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.00184	0.00347	CcSEcCtD
Dihydroxyaluminium—Infection—Delavirdine—acquired immunodeficiency syndrome	0.00183	0.00345	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00183	0.00345	CcSEcCtD
Dihydroxyaluminium—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.00181	0.00341	CcSEcCtD
Dihydroxyaluminium—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.0018	0.0034	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.0018	0.00339	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00179	0.00336	CcSEcCtD
Dihydroxyaluminium—Pain—Indinavir—acquired immunodeficiency syndrome	0.00174	0.00328	CcSEcCtD
Dihydroxyaluminium—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00174	0.00328	CcSEcCtD
Dihydroxyaluminium—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.00174	0.00328	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.00173	0.00326	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.00173	0.00326	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00172	0.00325	CcSEcCtD
Dihydroxyaluminium—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00172	0.00325	CcSEcCtD
Dihydroxyaluminium—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.00172	0.00324	CcSEcCtD
Dihydroxyaluminium—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.00172	0.00324	CcSEcCtD
Dihydroxyaluminium—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.0017	0.00321	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.0017	0.0032	CcSEcCtD
Dihydroxyaluminium—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00167	0.00315	CcSEcCtD
Dihydroxyaluminium—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00167	0.00314	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.00166	0.00313	CcSEcCtD
Dihydroxyaluminium—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.00166	0.00313	CcSEcCtD
Dihydroxyaluminium—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00166	0.00313	CcSEcCtD
Dihydroxyaluminium—Pain—Efavirenz—acquired immunodeficiency syndrome	0.00165	0.0031	CcSEcCtD
Dihydroxyaluminium—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00164	0.00309	CcSEcCtD
Dihydroxyaluminium—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.00164	0.00309	CcSEcCtD
Dihydroxyaluminium—Infection—Saquinavir—acquired immunodeficiency syndrome	0.00163	0.00307	CcSEcCtD
Dihydroxyaluminium—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.00162	0.00305	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.00161	0.00303	CcSEcCtD
Dihydroxyaluminium—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00161	0.00303	CcSEcCtD
Dihydroxyaluminium—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.0016	0.00302	CcSEcCtD
Dihydroxyaluminium—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.00159	0.003	CcSEcCtD
Dihydroxyaluminium—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00158	0.00297	CcSEcCtD
Dihydroxyaluminium—Pain—Delavirdine—acquired immunodeficiency syndrome	0.00157	0.00297	CcSEcCtD
Dihydroxyaluminium—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.00156	0.00295	CcSEcCtD
Dihydroxyaluminium—Infection—Lamivudine—acquired immunodeficiency syndrome	0.00155	0.00293	CcSEcCtD
Dihydroxyaluminium—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00155	0.00292	CcSEcCtD
Dihydroxyaluminium—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.00153	0.00288	CcSEcCtD
Dihydroxyaluminium—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.00153	0.00288	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.00152	0.00287	CcSEcCtD
Dihydroxyaluminium—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.0015	0.00283	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.0015	0.00283	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.0015	0.00282	CcSEcCtD
Dihydroxyaluminium—Nausea—Stavudine—acquired immunodeficiency syndrome	0.0015	0.00282	CcSEcCtD
Dihydroxyaluminium—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00147	0.00278	CcSEcCtD
Dihydroxyaluminium—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.00146	0.00276	CcSEcCtD
Dihydroxyaluminium—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.00146	0.00275	CcSEcCtD
Dihydroxyaluminium—Pain—Ritonavir—acquired immunodeficiency syndrome	0.00146	0.00274	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.00146	0.00274	CcSEcCtD
Dihydroxyaluminium—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00145	0.00273	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.00142	0.00267	CcSEcCtD
Dihydroxyaluminium—Pain—Saquinavir—acquired immunodeficiency syndrome	0.0014	0.00264	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.00139	0.00263	CcSEcCtD
Dihydroxyaluminium—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00139	0.00262	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.00136	0.00256	CcSEcCtD
Dihydroxyaluminium—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.00135	0.00255	CcSEcCtD
Dihydroxyaluminium—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00135	0.00254	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.00135	0.00254	CcSEcCtD
Dihydroxyaluminium—Pain—Lamivudine—acquired immunodeficiency syndrome	0.00134	0.00252	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.00132	0.00248	CcSEcCtD
Dihydroxyaluminium—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.0013	0.00245	CcSEcCtD
Dihydroxyaluminium—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.0013	0.00245	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.0013	0.00244	CcSEcCtD
Dihydroxyaluminium—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.00129	0.00244	CcSEcCtD
Dihydroxyaluminium—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00127	0.0024	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.00126	0.00237	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.00125	0.00236	CcSEcCtD
Dihydroxyaluminium—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.00124	0.00234	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.00124	0.00233	CcSEcCtD
Dihydroxyaluminium—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.00122	0.00231	CcSEcCtD
Dihydroxyaluminium—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.00122	0.00229	CcSEcCtD
Dihydroxyaluminium—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00121	0.00228	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00121	0.00227	CcSEcCtD
Dihydroxyaluminium—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.00117	0.00221	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.00116	0.00219	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.00115	0.00217	CcSEcCtD
Dihydroxyaluminium—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.00114	0.00215	CcSEcCtD
Dihydroxyaluminium—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00113	0.00212	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00112	0.00211	CcSEcCtD
Dihydroxyaluminium—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00109	0.00206	CcSEcCtD
Dihydroxyaluminium—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00108	0.00204	CcSEcCtD
Dihydroxyaluminium—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.00108	0.00204	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.00107	0.00202	CcSEcCtD
Dihydroxyaluminium—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.00104	0.00196	CcSEcCtD
Dihydroxyaluminium—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00103	0.00195	CcSEcCtD
Dihydroxyaluminium—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.00101	0.00191	CcSEcCtD
Dihydroxyaluminium—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000994	0.00187	CcSEcCtD
Dihydroxyaluminium—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000973	0.00183	CcSEcCtD
Dihydroxyaluminium—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000928	0.00175	CcSEcCtD
